Neutralization of IFN‐&ggr; reverts clinical and laboratory features in a mouse model of macrophage activation syndrome

[1]  V. Buatois,et al.  Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis , 2016, Translational Research.

[2]  W. Ferlin,et al.  Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis , 2016, Annals of the rheumatic diseases.

[3]  A. Horne,et al.  Macrophage activation syndrome in the era of biologic therapy , 2016, Nature Reviews Rheumatology.

[4]  A. Fischer,et al.  Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice. , 2016, Blood.

[5]  C. Wouters,et al.  Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis , 2016, The Journal of Immunology.

[6]  W. Ferlin,et al.  A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH , 2015 .

[7]  C. Wouters,et al.  Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. , 2015, Rheumatology.

[8]  S. Holland,et al.  Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-γ receptor deficiency. , 2015, The Journal of allergy and clinical immunology.

[9]  R. Locksley,et al.  A Novel Model for IFN-γ–Mediated Autoinflammatory Syndromes , 2015, The Journal of Immunology.

[10]  G. Schulert,et al.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. , 2015, Annual review of medicine.

[11]  J. Szustakowski,et al.  Whole‐Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic Lymphohistiocytosis , 2014, Arthritis & rheumatology.

[12]  B. Prakken,et al.  Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA , 2014, Nature Reviews Rheumatology.

[13]  R. Cron,et al.  Genetic Defects in Cytolysis in Macrophage Activation Syndrome , 2014, Current Rheumatology Reports.

[14]  C. Wouters,et al.  Systemic Juvenile Idiopathic Arthritis–like Syndrome in Mice Following Stimulation of the Immune System With Freund's Complete Adjuvant: Regulation by Interferon‐γ , 2014, Arthritis & rheumatology.

[15]  G. Schulert,et al.  Macrophage activation syndrome and cytokine-directed therapies. , 2014, Best practice & research. Clinical rheumatology.

[16]  E. Behrens,et al.  Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. , 2013, Arthritis and rheumatism.

[17]  F. De Benedetti,et al.  Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome , 2013, The Journal of Rheumatology.

[18]  C. Wouters,et al.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[19]  S. Thornton,et al.  The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. , 2012, Arthritis and rheumatism.

[20]  Yongmin Tang,et al.  Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. , 2012, The Journal of pediatrics.

[21]  R. Cron,et al.  Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment , 2012, Genes and Immunity.

[22]  S. Petrini,et al.  Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. , 2012, Arthritis and rheumatism.

[23]  M. Jordan,et al.  Hemophagocytic lymphohistiocytosis: updates and evolving concepts , 2012, Current opinion in pediatrics.

[24]  J. Aliberti,et al.  Hemophagocytosis causes a consumptive anemia of inflammation , 2011, The Journal of experimental medicine.

[25]  G. Koretzky,et al.  Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. , 2011, The Journal of clinical investigation.

[26]  A. Ramanan,et al.  Review of haemophagocytic lymphohistiocytosis , 2010, Archives of Disease in Childhood.

[27]  N. Wulffraat,et al.  Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. , 2010, Rheumatology.

[28]  Lionel B Ivashkiv,et al.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. , 2009, Immunity.

[29]  A. Fischer,et al.  Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice , 2009, EMBO molecular medicine.

[30]  D. Glass,et al.  Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. , 2008, Arthritis and rheumatism.

[31]  Sherry Thornton,et al.  Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. , 2007, Arthritis and rheumatism.

[32]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[33]  Paul Kellam,et al.  Specific gene expression profiles in systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[34]  A. Martini,et al.  Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? , 2005, Arthritis and rheumatism.

[35]  C. Wouters,et al.  Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. , 2005, Blood.

[36]  C. Wouters,et al.  Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. , 2005, Blood.

[37]  P. Marrack,et al.  An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. , 2004, Blood.

[38]  H. Takada,et al.  Increased serum levels of interferon‐γ‐inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis , 2003, Clinical and experimental immunology.

[39]  E. Goldmuntz,et al.  Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. , 2003, The Journal of pediatrics.

[40]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[41]  N. Wulffraat,et al.  Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. , 2003, Rheumatology.

[42]  G. Ciliberto,et al.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. , 1997, The Journal of clinical investigation.